← FDA DRUG APPROVALS

FDA ANDA · ANDA091426

SPIRONOLACTONE

Sponsor: AMNEAL PHARMS

APPLICATION
ANDA091426
TYPE
ANDA
ORIGINAL APPROVAL
2010-07-02
LATEST ACTION
2023-06-28
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

SPIRONOLACTONEPrescription
SPIRONOLACTONE 100MG · TABLET · ORAL
SPIRONOLACTONEPrescription
SPIRONOLACTONE 25MG · TABLET · ORAL
SPIRONOLACTONEPrescription
SPIRONOLACTONE 50MG · TABLET · ORAL

Approval history

2023-06-28Labeling · Supplement 26 · standardAP
2021-02-22Labeling · Supplement 17 · standardAP
2019-08-05Labeling · Supplement 9 · standardAP
2015-12-02Labeling · Supplement 6 · standardAP
2015-12-02Labeling · Supplement 4 · standardAP
2015-12-02Labeling · Supplement 7 · standardAP
2015-12-02Manufacturing (CMC) · Supplement 5 · unknownAP
2015-12-02Labeling · Supplement 3 · standardAP
2011-11-28Labeling · Supplement 2AP
2010-07-02OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →